Resistant Hypertension Clinical Trial
Official title:
Efficacy and Safety of Remote Ischemic Conditioning for the Treatment of Resistant Hypertension: a Pilot Study
This study aims to explore the efficacy and safety of remote ischemia adaptation for the treatment of resistant hypertension.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | March 30, 2023 |
Est. primary completion date | February 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 80 Years |
Eligibility | Inclusion Criteria: - Aged 30~80 years old; - Taking = 3 antihypertensive drugs (including one diuretic) for more than 4 weeks regularly; - Office blood pressure = 140/90mmhg, and 24 h average blood pressure = 130/80 mmHg; - Willing to participate in the study, follow the study protocol, and provide informed consent. Exclusion Criteria: - Secondary hypertension; - eGFR<45ml/min/1.73m2; - Office blood pressure =180/110 mmHg, and 24 h average blood pressure = 170/100 mmHg; - Hypertensive crisis occurred within 3 months; - Type 1 diabetes; - Cardiovascular events occurred within 3 months; - Atrial fibrillation; - Presence of any severe disease that adversely affects the subject or study; - Patients with contraindication for remote ischemic conditioning, such as vascular injury, soft tissue injury, orthopedic injury, or arm infection; - Pregnancy, lactation, or planned pregnancy; - Patients not suitable for this trial considered by researchers for other reasons; - Participation in another device or drug trial simultaneously. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ji Xunming,MD,PhD |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes of 24 h average systolic blood pressure | Changes of 24 h average systolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of 24 h average diasolic blood pressure | Changes of 24 h average diasolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of daytime average systolic blood pressure | Changes of daytime average systolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of daytime average diastolic blood pressure | Changes of daytime average diastolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of nighttime average systolic blood pressure | Changes of nighttime average systolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of nighttime average diastolic blood pressure | Changes of nighttime average diastolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of 24 h average heart rate | Changes of 24 h average heart rate from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of office systolic blood pressure | Changes of office systolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of office diastolic blood pressure | Changes of office diastolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of home systolic blood pressure | Changes of home systolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks | |
Secondary | Changes of home diastolic blood pressure | Changes of home diastolic blood pressure from baseline to 8 weeks | from baseline to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05545059 -
Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT04388124 -
VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
|
Phase 2 | |
Withdrawn |
NCT01939392 -
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06228677 -
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
|
||
Recruiting |
NCT04213963 -
Prospective Study on Primary Aldosteronism in Resistant Hypertension
|
||
Recruiting |
NCT05563077 -
Aerobic Exercise and Resistant Hypertension
|
N/A | |
Recruiting |
NCT03758196 -
Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)
|
N/A | |
Active, not recruiting |
NCT03179800 -
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
|
N/A | |
Completed |
NCT04519658 -
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
|
Phase 2 | |
Not yet recruiting |
NCT05552300 -
Superselective Adrenal Arterial Embolization for Resistant Hypertension
|
N/A | |
Completed |
NCT04345198 -
Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension
|
N/A | |
Active, not recruiting |
NCT05562934 -
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
|
Phase 2 | |
Recruiting |
NCT06034743 -
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
|
Phase 3 | |
Withdrawn |
NCT02926495 -
Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.
|
N/A | |
Active, not recruiting |
NCT02670681 -
Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects
|
N/A | |
Completed |
NCT02572024 -
The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)
|
N/A | |
Terminated |
NCT02295683 -
Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
|
||
Completed |
NCT02001350 -
Carotid Ultrasound Study
|
N/A | |
Recruiting |
NCT04331691 -
Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension
|
Phase 4 | |
Recruiting |
NCT04637152 -
Sacubitril/Valsartan in Resistant Hypertension
|
Phase 2 |